Sanofi Is Weighing a Takeover of Insmed, Bloomberg Reports

A lung-drug maker valued at $26.28 billion would dwarf the French group's usual deal size, weeks after it told investors to expect bigger acquisitions.

Sources

Sources & evidence

What “Source checked” means

SNYLatest quoteINSMLatest quote

Sanofi is weighing a takeover of Insmed, the fast-growing lung-drug maker, Bloomberg News reported on Thursday, citing people familiar with the matter.

Bloomberg's report, carried by Reuters on Thursday, describes study, not action. Sanofi is speaking with advisers as it weighs a potential deal.

Neither company confirmed anything. Sanofi said it does not comment on market rumors, and Insmed did not immediately respond to a request for comment.

Insmed shares rose sharply on Thursday after the report. The United States session was still open at publication, so no closing move is printed here.

A target built on two lung drugs

Insmed makes medicines for serious rare and respiratory diseases. Its two marketed drugs are Brinsupri and Arikayce, both aimed at lung conditions.

Total revenue reached $524.4 million in the third quarter of 2026. That was up 268% from $142.3 million a year earlier, the company reported on October 29.

Brinsupri brought in $400.1 million in the quarter, up 29% from the second quarter. It treats non-cystic fibrosis bronchiectasis, a chronic lung condition.

In October, Brinsupri became the first and only approved treatment for that condition in Japan. Arikayce added $124.4 million, up 9% year over year.

The company is still loss-making despite that growth. Its third-quarter net loss was $100.3 million, narrower than $370.0 million a year earlier.

Insmed also raised guidance on October 29. It lifted the low end of full-year Brinsupri guidance to $1.35 billion and Arikayce guidance to $460 million.

One link already connects the two boards. In October, Insmed appointed Paul Hudson, Sanofi's former chief executive, to its board of directors.

Why Sanofi has said it will shop bigger

The reported interest lands weeks after Sanofi told investors to expect larger deals. On October 30, it raised 2026 guidance for a second time.

Chief Executive Belen Garijo said business development and mergers would be critical. The company framed deals as protection for earnings beyond 2030.

Finance chief Francois-Xavier Roger said Sanofi was considering deals larger than its historical range. That range is 2 billion to 5 billion euros.

He pointed to late-stage candidates and products already on the market. The focus areas he named included immunology and rare diseases.

The pressure behind the search is concentration. Dupixent generated 5.7 billion euros in the third quarter, nearly 40% of Sanofi's total sales.

Dupixent loses patent protection in the early 2030s. Analysts estimate Sanofi has about 20 billion euros of deal capacity, an analyst estimate only.

Insmed's $26.28 billion market value sits far above that historical range. The comparison is the scale anchor, and the currencies are kept separate here.

What remains unknown

What remains unknown starts with whether talks advance at all. No bid, price, financing terms or agreement were reported by any source.

Whether Sanofi makes a formal approach is unknown. So is the price it might offer, and how any deal would be financed.

How Insmed's board would respond is also unknown. Neither company has confirmed that discussions are taking place.

The tests that come next

The first test is confirmation. A statement from either company would turn reported talks into a disclosed process.

The second test is time. The report said any deal could still be weeks away, so silence in the coming days proves little.

The third test is price discipline. A formal approach would show whether Sanofi is ready to pay far above its historical range.

Sources & evidence

Source checked3 sources · 7 figures

Figure receipts

Every figure in this article, with the source it came from.

  • $524.4M Insmed total revenue, third quarter 2026

    As of Nov. 19, 2026

  • $400.1M Brinsupri revenue, third quarter 2026

    As of Nov. 19, 2026

  • $124.4M Arikayce revenue, third quarter 2026

    As of Nov. 19, 2026

  • $100.3M Insmed net loss, third quarter 2026

    As of Nov. 19, 2026

  • $1.35B Brinsupri full-year 2026 guidance, low end after the October raise

    As of Nov. 19, 2026

  • $460M Arikayce full-year 2026 guidance, low end after the October raise

    As of Nov. 19, 2026

  • $26.28B Insmed market valuation

    As of Nov. 19, 2026

As of Thursday, Nov. 19, 2026.

TickerGrove house illustration for deals coverage: stacked coins and a key

Get the Morning Brief — Weekday Morning Brief · Saturday Weekend Brief · Sunday Week Ahead

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

Disclaimer

TickerGrove is education and journalism only. It is not investment advice, not a broker-dealer, and not a recommendation to buy, sell, or hold any security.

Nothing on this site is a pick or a return promise. Official economic prints and company filings are dated observations. External quote links open a separate service; TickerGrove does not host those prices.

Companies · All stories